Leveraging his 34 years of large pharma experience at Pfizer, Inc., Larry's goal is to work with innovative biotech companies, applying DMPK assays in drug discovery and efficiently move candidates through early phase development.

Larry received his PhD. In Pharmacology from the University of Minnesota and subsequently joined the Drug Metabolism (DMPK) department with Pfizer (Groton, CT site). As the DMPK rep, he has worked with matrix teams in drug discovery and development stages, including the development and approval of Zoloft, Geodon and Chantix. He retired as a Senior Director for Enzymology and Transporter Sciences groups, having been responsible for the experimental study conduct in these disciplines for small molecule programs across all therapeutic areas. A key role for this group was to enable project teams by addressing ADME issues through innovative approaches and new methodologies.   

585 Massachusetts Avenue
Cambridge, MA 02139
info@clearcreekbio.com